Loading...
Loading...
- The European Commission (EC) has granted marketing authorization to Seagen Inc's (NASDAQ: SGEN) TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, to treat adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
- TUKYSA is an oral, small-molecule tyrosine kinase inhibitor of HER2, a protein that contributes to cancer cell growth.
- The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for TUKYSA in December last year.
- Price Action: SGEN stock slips 0.07% at $171.9 in premarket trading hours on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in